Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply

scientific article published on 01 May 2019

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S2213-8587(19)30080-4
P698PubMed publication ID31003622

P2093author name stringJosef Coresh
Ron T Gansevoort
Lesley A Inker
Hiddo J L Heerspink
P2860cites workDrug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-AnalysisQ35903126
Combined angiotensin inhibition for the treatment of diabetic nephropathyQ46129784
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Q46426098
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studiesQ91009115
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trialsQ91009119
P433issue5
P921main subjectchronic renal insufficiencyQ736715
P304page(s)336-337
P577publication date2019-05-01
P1433published inThe Lancet: Diabetes & EndocrinologyQ27725107
P1476titleChange in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply
P478volume7

Reverse relations

cites work (P2860)
Q90066163Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
Q92435011The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists